Cynata Therapeutics Limited (FRA:51S)

Cynata Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Other Revenue	1.89	2.32	1.65	7.77	1.55
Revenue	1.89	2.32	1.65	7.77	1.55
Revenue Growth (YoY)	-18.59%	39.98%	-78.71%	402.60%	-77.95%
Gross Profit	1.89	2.32	1.65	7.77	1.55
Selling, General & Admin	2.07	1.93	1.65	1.92	1.76
Research & Development	7.4	8.68	12.39	8.82	3.78
Amortization of Goodwill & Intangibles	0.28	0.28	0.28	0.28	0.28
Other Operating Expenses	1.49	1.42	1.89	1.78	1.73
Operating Expenses	11.5	12.55	16.54	13.84	9.08
Operating Income	-9.61	-10.23	-14.89	-6.07	-7.53
Interest & Investment Income	0.23	0.42	0.35	0.06	0.09
Currency Exchange Gain (Loss)	-0.01	0.07	0.26	0.56	-0.3
EBT Excluding Unusual Items	-9.39	-9.74	-14.28	-5.45	-7.74
Other Unusual Items	-	-	-	-	0.05
Pretax Income	-9.39	-9.74	-14.28	-5.45	-7.69
Net Income	-9.39	-9.74	-14.28	-5.45	-7.69
Net Income to Common	-9.39	-9.74	-14.28	-5.45	-7.69
Shares Outstanding (Basic)	205	180	145	143	130
Shares Outstanding (Diluted)	205	180	145	143	130
Shares Change (YoY)	14.09%	23.80%	1.27%	9.85%	24.80%
EPS (Basic)	-0.05	-0.05	-0.10	-0.04	-0.06
EPS (Diluted)	-0.05	-0.05	-0.10	-0.04	-0.06
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-509.82%	-441.78%	-899.97%	-78.09%	-487.33%
Profit Margin	-498.14%	-420.82%	-863.05%	-70.08%	-497.38%
EBITDA	-9.33	-9.95	-14.61	-5.79	-7.25
EBITDA Margin	-	-	-	-74.48%	-
D&A For EBITDA	0.28	0.28	0.28	0.28	0.28
EBIT	-9.61	-10.23	-14.89	-6.07	-7.53
EBIT Margin	-	-	-	-78.09%	-
Revenue as Reported	2.11	2.73	2.01	7.84	1.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.